RNAble is a preclinical biotechnology company developing a potent small-molecule inhibitor targeting FTO, a key driver of oncogenic RNA biology. Mechanistic studies have led to the identification of a specific biomarker that predicts pan-cancer sensitivity to the inhibitor across both hematological and solid malignancies.
Key highlights of RNAble's lead candidate:
• Demonstrates strong in vivo efficacy and superior antitumor activity compared to standard-of-care therapies in AML models.
• Shows promising efficacy in preclinical models of biomarker-selected solid tumors.
• Features a novel, validated mechanism of action that induces cancer cell death via RNA-mediated mitotic catastrophe followed by apoptosis, with potential to overcome resistance to current therapies.
• Exhibits strong oral bioavailability and a favorable safety profile.
• Expected IND submission in 2026.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Ilan Ramon Street 2, 3rd Floor,israel
- Industry
- Biotechnology
- Keywords
- RNA, Cancer, Small Molecule.
- HQ
- Ness Ziona
Rnable Questions
Rnable's website is https://www.futurx.co.il/portfolio/rnable/
Rnable's LinkedIn profile is https://il.linkedin.com/company/rnable
Rnable has
6 employees.
View email and phone details for 6
employees at Rnable.
Rnable's industry is
Biotechnology
Rnable's top competitors are
Scinai Immunotherapeutics Ltd.,
Futurx,
Epeius Pharma,
Catchme Therapeutics,
Aummune,
Cytoreason,
Circuit-Bio Ltd,
Kanso Diagnostics,
Mitocarex Bio Ltd,
Biolinerx.
Rnable's categories are Biotechnology
Rnable's founding year is 2021
